FDA-approved medication
Wegovy (semaglutide)
Key facts
Last reviewed: 2026-11-04- •FDA label says "WEGOVY (semaglutide) injection, for subcutaneous use".
- •FDA label says "Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals."
- •FDA label says "Inject subcutaneously in the abdomen, thigh, or upper arm."
- •FDA label says "WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in: o adults and pediatric patients aged 12 years and older with obesity. ( 1 ) o adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) • for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults."
FDA-approved to reduce excess body weight and maintain weight reduction long term. Read the dose schedule and safety information, and check the official prescribing information. Confirm costs and coverage with your pharmacy, insurer, or the manufacturer.
semaglutide · prefilled, single-dose pen · once weekly, subcutaneous
- Active ingredient
- semaglutide
- Dosage form (label)
- Injection: prefilled, single-dose pen
- Schedule (label)
- Once weekly, subcutaneous
- Strengths (label)
- Wegovy injection is supplied as 0.25, 0.5, 1, 1.7 and 2.4 mg single-dose pens or syringes and, as Wegovy HD, a 7.2 mg pen. Your prescriber chooses the dose; see the current prescribing information.FDA announcement, March 19, 2026 · Wegovy prescribing information (DailyMed). Accessed November 4, 2026.
- Manufacturer
- Novo Nordisk A/S (per label)
Brand names are trademarks of their respective owners; this site is not affiliated with them.

FDA label
Wegovy dose steps (FDA label)
- 0.25 mgWeeks 1–4Starting dose
- 0.5 mgWeeks 5–8Dose step
- 1 mgWeeks 9–12Dose step
- 1.7 mgWeeks 13–16Dose step
- 2.4 mgWeek 17 onwardLabel maintenance dose
FDA label answers
Common questions about Wegovy
All answers are taken directly from the official FDA prescribing information (FDA Prescribing Information (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, SPL version 19, revised 06/2026)).
Who is Wegovy injection approved for?
FDA label says "WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in: o adults and pediatric patients aged 12 years and older with obesity. ( 1 ) o adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) • for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults."
How often is Wegovy injection taken?
FDA label says "Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals."
What are the most common side effects listed on the label for Wegovy injection?
FDA label says "Most common adverse reactions (incidence ≥5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss."
Is there a boxed warning on the Wegovy label?
Yes. FDA label says "WARNING: RISK OF THYROID C-CELL TUMORS" — "In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures."
What is the recommended dose escalation schedule for Wegovy injection?
FDA label says "Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule in Table 1, titrating every 4 weeks to achieve the maintenance dosage."
Next Steps: Evaluating Wegovy for Your Care Plan
Transition from drug facts to clinical action. Estimate potential out-of-pocket expenses, generate consultation questions, and verify eligibility.
Out-of-Pocket Expense Modeling
Estimate what you might pay each month based on manufacturer assistance terms and employer benefit design.
Consultation & Lab Checklist
Arrive at your appointment prepared with essential baseline bloodwork requirements and contraindication screens.
BMI Qualification & Directory
Verify your body mass index against official FDA prescribing label requirements and locate qualified clinicians.
Editorial & Regulatory Standard: TrimSoMo is an independent, non-commercial healthcare information platform. Estimated out-of-pocket costs and savings card parameters reflect publicly published 2026 manufacturer program guidelines and do not guarantee individual insurance coverage or pharmacy dispensing prices. Prescriptions require clinical evaluation by a licensed physician.
Before Starting Wegovy
Gradual Dose Titration
Per the FDA label, doses start low and increase over several months to help reduce gastrointestinal side effects. Your clinician sets your schedule. Review post-marketing data in our GLP-1 side effects from FDA labels → FAERS reports do not prove cause.
Lifestyle & Nutrition Support
In clinical studies, medication was used together with a reduced-calorie diet and increased physical activity.
Long-Term Plan
Talk with your clinician before changing or stopping treatment.
In-Depth Clinical Guides
Explore our clinical reviews, FDA label comparisons, and insurance navigation guides for Wegovy.
Dose Escalation Schedule
Wegovy titration steps from 0.25 mg starter to 2.4 mg maintenance, and 7.2 mg label rules.
Ozempic vs. Wegovy Differences
Same active semaglutide molecule, but separate FDA indications, pen designs, and dosages.
Prior Authorization & Appeals Guide
Criteria, chart documentation, and step-by-step formulary navigation for Wegovy.
Managing Side Effects
Clinical protocols for gastrointestinal adaptation and hydration during escalation.
Exploring non-injectable options?
Some oral GLP-1 medicines are FDA-approved and others are still in development. The list shows each medicine's status and source.